Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Weekly Cisplatin plus S-1 with Concurrent Proton or Photon Radiotherapy in Elderly Inoperable Stage III NSCLC
jRCT1041230096Phase 1Not yet recruiting
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin and tegafur in non-small cell lung cancer (NSCLC). Primary endpoint: Maximum tolerated dose of weekly cisplatin. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
cisplatintegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1041230096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230096.